Holen Sie sich die Stockscreener-App
11.33
5.25%
0.565
Handel nachbörslich:
11.61
0.28
+2.47%
Regenxbio Inc Aktie (RGNX) Neueste Nachrichten
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Walleye Capital LLC Invests $2.44 Million in REGENXBIO Inc. $RGNX - MarketBeat
Regenxbio Stock Price Forecast. Should You Buy RGNX? - StockInvest.us
REGENXBIO (NASDAQ:RGNX) Rating Increased to Hold at Zacks Research - MarketBeat
Assenagon Asset Management S.A. Has $2.03 Million Position in REGENXBIO Inc. $RGNX - MarketBeat
FDA Commissioner Refers To Rare Disease Drug With Associated Morbidity: Analysts Are Divided If Makary Meant Regenxbio Or Uniqure’s Experimental Therapy - Stocktwits
(RGNX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
HC Wainwright Has Pessimistic View of REGENXBIO Q3 Earnings - MarketBeat
REGENXBIO’s Multi-Catalyst Setup Is Hard To Ignore (Rating Upgrade) (NASDAQ:RGNX) - Seeking Alpha
Regenxbio posts strong Q with 407% revenue grow... - Pluang
H.C. Wainwright lowers Regenxbio stock price target on equity offering By Investing.com - Investing.com UK
RGNX Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
H.C. Wainwright lowers Regenxbio stock price target on equity offering - Investing.com
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $23 - Moomoo
Dimensional Fund Advisors LP Increases Stock Position in REGENXBIO Inc. $RGNX - MarketBeat
RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
Regenxbio Inc (RGNX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RGNX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Bank of America Securities Reaffirms Their Buy Rating on RegenXBio (RGNX) - The Globe and Mail
REGENXBIO (RGNX) Stock Drops Despite Profit Surprise And Longer Cash Runway - Sahm
REGENXBIO (NASDAQ:RGNX) Rating Increased to Hold at Wall Street Zen - MarketBeat
Regenxbio Seen on Track for Duchenne Approval as Data Strengthens, RBC Says - marketscreener.com
REGENXBIO (NASDAQ:RGNX) Shares Down 6.1%Here's Why - MarketBeat
REGENXBIO Price Target Maintained With a $12.00/Share by Barclays - Moomoo
Barclays downgrades Regenxbio stock rating on regulatory uncertainty By Investing.com - Investing.com UK
Barclays Reiterates "Equal Weight" Rating for REGENXBIO (NASDAQ:RGNX) - MarketBeat
Barclays downgrades Regenxbio stock rating on regulatory uncertainty - Investing.com
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits
Barclays Downgrades REGENXBIO to Equalweight From Overweight, $12 Price Target - marketscreener.com
REGENXBIO Q2 Earnings Call Highlights - MarketBeat
Barclays downgrades Regenxbio stock rating on regulatory concerns By Investing.com - Investing.com Australia
Morgan Stanley Adjusts Price Target on REGENXBIO to $18 From $16, Maintains Overweight Rating - marketscreener.com
Barclays downgrades Regenxbio stock rating on regulatory concerns - Investing.com
REGENXBIO Inc. (RGNX) Stock Analysis: Exploring a 101% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
REGENXBIO (NASDAQ:RGNX) Issues Earnings Results, Beats Expectations By $0.35 EPS - MarketBeat
RGNX DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds - The National Law Review
REGENXBIO Inc. Stock 12‑Month Price Target Raised to $26.17, Implies 149% Upside - TradingView
Earnings call transcript: REGENXBIO beats on Q2 2026 EPS, shares rise premarket - Investing.com Nigeria
Regenxbio Inc (RGNX) (Q2 2026) Earnings Call Highlights: Cash Ru - GuruFocus
Form 8K Regenxbio Inc For: 6 August By Investing.com - Investing.com South Africa
Regenxbio (RGNX) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
RGNX: Milestones in gene therapy pipeline and $310M+ cash position drive outlook through 2027 - tradingview.com
REGENXBIO Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Transcript : REGENXBIO Inc., Q2 2026 Earnings Call, Aug 06, 2026 - marketscreener.com
REGENXBIO Inc. reports results for the quarter ended June 30Earnings Summary - tradingview.com
Regenxbio: Q2 Earnings Snapshot - Yahoo Finance
REGENXBIO Inc. Q2 2026: Revenue $108M, EPS $0.43— 10-Q Summary - TradingView
REGENXBIO Q2 revenue rises to $108 million as RGX-202 BLA nears - Quiver Quantitative
REGENXBIO Inc. Quarterly Earnings Report - stocktitan.net
REGENXBIO Q2 2026 Earnings: $100 Million Milestone Drives a Quarterly Profit - TradingKey
REGENXBIO reports Q2 2026: $108.0M revenue, $22.7M net income, cash pro forma >$310M - TradingView
REGENXBIO (Nasdaq: RGNX) turns Q2 profit on $100M AbbVie milestone - Stock Titan
REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights - TradingView
RGNX Looks 33.1% Undervalued on GF Value™ Despite Possible Value Trap - GuruFocus
1.80%
1.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):